. | Screening history . | |||
---|---|---|---|---|
. | Regular . | Sporadic . | Pre-diagnostic . | None . |
N (%) | 37 (16%) | 34 (15%) | 66 (29%) | 88 (39%) |
Mean age | 41* | 49* | 54* | 54* |
Stage I | 76%** | 62% | 58% | 35%** |
Stage II–IV | 24%** | 38% | 42% | 65%** |
Squamous cell | 54% | 59% | 74% | 68% |
Adeno/adenosquamous | 43% | 41% | 23% | 30% |
. | Screening history . | |||
---|---|---|---|---|
. | Regular . | Sporadic . | Pre-diagnostic . | None . |
N (%) | 37 (16%) | 34 (15%) | 66 (29%) | 88 (39%) |
Mean age | 41* | 49* | 54* | 54* |
Stage I | 76%** | 62% | 58% | 35%** |
Stage II–IV | 24%** | 38% | 42% | 65%** |
Squamous cell | 54% | 59% | 74% | 68% |
Adeno/adenosquamous | 43% | 41% | 23% | 30% |
*Mean age of the regular screening group is significantly different than all other groups (Student's t-test P < 0.01)
**χ2-test P < 0.00005
. | Screening history . | |||
---|---|---|---|---|
. | Regular . | Sporadic . | Pre-diagnostic . | None . |
N (%) | 37 (16%) | 34 (15%) | 66 (29%) | 88 (39%) |
Mean age | 41* | 49* | 54* | 54* |
Stage I | 76%** | 62% | 58% | 35%** |
Stage II–IV | 24%** | 38% | 42% | 65%** |
Squamous cell | 54% | 59% | 74% | 68% |
Adeno/adenosquamous | 43% | 41% | 23% | 30% |
. | Screening history . | |||
---|---|---|---|---|
. | Regular . | Sporadic . | Pre-diagnostic . | None . |
N (%) | 37 (16%) | 34 (15%) | 66 (29%) | 88 (39%) |
Mean age | 41* | 49* | 54* | 54* |
Stage I | 76%** | 62% | 58% | 35%** |
Stage II–IV | 24%** | 38% | 42% | 65%** |
Squamous cell | 54% | 59% | 74% | 68% |
Adeno/adenosquamous | 43% | 41% | 23% | 30% |
*Mean age of the regular screening group is significantly different than all other groups (Student's t-test P < 0.01)
**χ2-test P < 0.00005
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.